



SHEET 1 OF 1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
	APPLICANT BAR-OR et al.	
	FILING DATE February 13, 2002	GROUP ART 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
AP	AA	5,538,945	7/23/96	Pallenberg et al.	514	6	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

AP	AB	Battegay, E.J., "Angiogenesis: Mechanistic Insights, Neovascular Diseases, and Therapeutic Prospects," <i>Journal of Molecular Medicine</i> , 1995, Vol. 73, pp. 333-346.

RECEIVED

RECEIVED

FEB 21 2003

TECH CENTER 1600/2900


TECH CENTER 1600/2900

EXAMINER AP	DATE CONSIDERED 9/14/04
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
	APPLICANT BAR-OR et al.	
	FILING DATE February 13, 2002	GROUP ART 1614


U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
<i>B</i>	1	6,084,093	7/4/00	Riley et al.	540	465	
<i>B</i>	2	6,083,758	7/4/00	Imperiali et al.	436	73	
<i>B</i>	3	6,022,879	2/8/00	Crow et al.	514	319	
<i>B</i>	4	6,017,888	1/25/00	Pallenberg et al.	514	19	
<i>B</i>	5	6,004,953	12/21/99	Volpin et al.	514	185	
<i>B</i>	6	5,994,339	11/30/99	Crapo et al.	514	185	
<i>B</i>	7	5,922,761	7/13/99	Lai	514	476	
<i>B</i>	8	5,906,996	5/25/99	Murphy	514	674	
<i>B</i>	9	5,888,522	3/30/99	Pickart	424	401	
<i>B</i>	10	5,874,573	2/23/99	Winchell et al.	540	465	
<i>B</i>	11	5,858,993	1/12/99	Pickart	514	60	
<i>B</i>	12	5,807,535	9/15/98	Smith et al.	424	1.65	
<i>B</i>	13	5,786,335	7/28/98	Cody et al.	514	17	
<i>B</i>	14	5,785,948	7/28/98	Itaya et al.	424	1.69	
<i>B</i>	15	5,780,594	7/14/98	Carter	530	363	
<i>B</i>	16	5,776,892	7/7/98	Counts et al.	514	11	
<i>B</i>	17	5,770,178	6/23/98	Itaya et al.	424	1.69	
<i>B</i>	18	5,739,395	4/14/98	Bergeron, Jr.	562	565	
<i>B</i>	19	5,710,172	1/20/98	Kukreja et al.	514	400	
<i>B</i>	20	5,683,907	11/4/97	Johnson	436	518	
<i>B</i>	21	5,670,645	9/23/97	Johnson	546	141	
<i>B</i>	22	5,670,627	9/23/97	Johnson	530	388.9	
<i>B</i>	23	5,663,301	9/2/97	Johnson	530	363	
<i>B</i>	24	5,654,160	8/5/97	Johnson	435	7.9	
<i>B</i>	25	5,650,134	7/22/97	Albert et al.	424	1.69	
<i>B</i>	26	5,639,624	6/17/97	Wagner et al.	435	7.92	


EXAMINER 	DATE CONSIDERED 9/14/04
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
	APPLICANT BAR-OR et al.	
	FILING DATE February 13, 2002	GROUP ART 1614

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
10	27	5,637,578	6/10/97	Riley et al.	514	186	
10	28	5,637,311	6/10/97	Pallenberg	424	434	
10	29	5,631,172	5/20/97	Johnson	436	543	
10	30	5,628,982	5/13/97	Lauffer et al.	424	9.363	
10	31	5,624,900	4/29/97	Suda et al.	514	13	
10	32	5,591,711	1/7/97	Koyama et al.	514	6	
10	33	5,585,466	12/17/96	Carter	530	363	
10	34	5,554,375	9/10/96	Pickart	424	401	
10	35	5,550,183	8/27/96	Pickart	514	6	
10	36	5,538,945	7/23/96	Pallenberg et al.	514	6	
10	37	5,527,522	6/18/96	Lauffer et al.	424	9.362	
10	38	5,503,987	4/2/96	Wagner et al.	435	7.94	
10	39	5,476,939	12/19/95	Johnson	546	141	
10	40	5,470,876	11/28/95	Proctor	514	492	
10	41	5,455,229	10/3/95	Hahn et al.	514	18	
10	42	5,422,096	6/6/95	Lauffer et al.	424	9.363	
10	43	5,382,431	1/17/95	Pickart	424	401	
10	44	5,380,747	1/10/95	Medford et al.	514	423	
10	45	5,348,943	9/20/94	Pickart	514	18	
10	46	5,290,519	3/1/94	Bar-Or et al.	522	61	
10	47	5,252,559	10/12/93	Kronholm et al.	514	18	
10	48	5,227,307	7/13/93	Bar-Or et al.	436	63	
10	49	5,214,032	5/25/93	Pickart	514	16	
10	50	5,177,061	1/5/93	Pickart	514	18	
10	51	5,164,367	11/17/92	Pickart	514	6	
10	52	5,145,838	9/8/92	Pickart	514	18	
10	53	5,135,913	8/4/92	Pickart	514	16	

EXAMINER 	DATE CONSIDERED 9/14/04
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
	APPLICANT BAR-OR et al.	
	FILING DATE February 13, 2002	GROUP ART 1614



*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
<i>AB</i>	54	5,120,831	6/9/92	Pickart	530	331	
<i>AB</i>	55	5,118,665	6/2/92	Pickart	514	6	
<i>AB</i>	56	5,104,865	4/14/92	Hider et al.	514	188	
<i>AB</i>	57	5,101,041	3/31/92	Troutner et al.	548	518	
<i>AB</i>	58	5,087,696	2/11/92	Parker et al.	540	465	
<i>AB</i>	59	5,059,588	10/22/91	Pickart	514	12	
<i>AB</i>	60	5,023,237	6/11/91	Pickart	514	18	
<i>AB</i>	61	4,912,118	3/27/90	Hider et al.	514	332	
<i>AB</i>	62	4,877,770	10/31/89	Pickart	514	18	
<i>AB</i>	63	4,810,693	3/7/89	Pickart	514	18	
<i>AB</i>	64	4,767,753	8/30/88	Pickart	514	18	
<i>AB</i>	65	4,760,051	7/26/88	Pickart	514	6	
<i>AB</i>	66	4,746,649	5/24/88	Raddatz et al.	514	18	
<i>AB</i>	67	4,684,624	8/4/87	Hosobuchi et al.	514	15	
<i>AB</i>	68	4,665,054	5/12/87	Pickart	514	18	
<i>AB</i>	69	4,591,648	5/27/86	Jones et al.	548	344	
<i>AB</i>	70	4,461,724	7/24/84	Konishi	260	112.5	
<i>AB</i>	71	4,025,499	5/24/77	Thomas	260	112.5	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
<i>AB</i>	72	WO 00/20840	4/2000	PCT	514	18		
<i>AB</i>	73	WO 00/20454	4/2000	PCT	514	18		
<i>AB</i>	74	WO 99/45907	9/1999	PCT	514	18		
<i>AB</i>	75	WO 99/39706	8/1999	PCT	514	18		


EXAMINER <i>AB</i>	DATE CONSIDERED <i>9/14/94</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
	APPLICANT BAR-OR et al.	
	FILING DATE February 13, 2002	GROUP ART 1614

<input checked="" type="checkbox"/>	76	WO 98/54138	12/1998	PCT				
<input checked="" type="checkbox"/>	77	EP 0613560 B1	10/1998	EPO				
<input checked="" type="checkbox"/>	78	WO 98/40071	9/1998	PCT				
<input checked="" type="checkbox"/>	79	WO 97/49409	12/1997	PCT				
<input checked="" type="checkbox"/>	80	WO 97/44313	11/1997	PCT				
<input checked="" type="checkbox"/>	81	719790	12/1995	EPO				
<input checked="" type="checkbox"/>	82	WO 94/26295	11/1994	PCT				
<input checked="" type="checkbox"/>	83	WO 93/23425	11/1993	PCT				
<input checked="" type="checkbox"/>	84	WO 93/10459	5/1993	PCT				
<input checked="" type="checkbox"/>	85	WO 91/17760	11/1991	PCT				
<input checked="" type="checkbox"/>	86	327263	1/1989	EPO				
<input checked="" type="checkbox"/>	87	JP 62116565	5/1987	Japan				
<input checked="" type="checkbox"/>	88	WO 00/21941	4/20/00	PCT				


OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

<input checked="" type="checkbox"/>	89	"Angiogenesis Inhibitors," found at http://www.cancerprotocol.com/angiogenesis_inhibitors.html , January 28, 2002, 1 page
<input checked="" type="checkbox"/>	90	"Metal Heads," from New Scientist, 26/8/00, found at http://purdeyenvironment.com/Full%20New%20scientist0001.htm , 6 pages
<input checked="" type="checkbox"/>	91	"Metal-Binding Groups of Proteins: A. Evidence for Specific Donor Atoms," Chapter IV, pp. 61-99
<input checked="" type="checkbox"/>	92	"The Role of Copper in the Angiogenesis Process," found at http://www.cancerprotocol.com/role_of_copper.html , January 28, 2002, 2 pages
<input checked="" type="checkbox"/>	93	"Toxicity and Physicochemical Properties of Metal: Coordination and Chelation," Ch. 4, pp. 115-122
<input checked="" type="checkbox"/>	94	Adman, <i>Advances in Protein Chemistry</i> , 42:145-197 (1991)
<input checked="" type="checkbox"/>	95	Afanas'ev, <i>Superoxide Ion: Chemistry and Biological Implications</i> , Vol. I, pp. 26, 51, 147, 168-196, 248-266 (CRC Press, Boca Raton, FL) (1989)
<input checked="" type="checkbox"/>	96	Aitken, <i>Mol. Biotech.</i> , 12:241-253 (1999)
<input checked="" type="checkbox"/>	97	Ames et al., <i>Proc. Natl. Acad. Sci. USA</i> , 90:7915-7922 (1993)
<input checked="" type="checkbox"/>	98	Atanaslu et al., <i>Mol. Cell. Biochem.</i> , 189:127-135 (1998)
<input checked="" type="checkbox"/>	99	Atwood et al., <i>J. Biol. Chem.</i> , 273(21):12817-12826 (1998)

EXAMINER 	DATE CONSIDERED 9/14/02
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
	APPLICANT BAR-OR et al.	
	FILING DATE February 13, 2002	GROUP ART 1614

100	Aust, <i>Bibl. Nutr. Dieta</i> , Basel, Karger, No. 43, pp. 266-277 (1989)
101	Bal et al., <i>Chem. Res. Toxicol.</i> , 10(8):906-914 (1997)
102	Bal et al., <i>Chem. Res. Toxicol.</i> , 10:915-921 (1997)
103	Bar-Or et al., <i>Biochem. Biophys. Res. Commun.</i> , 284:856-862 (2001)
104	Bar-Or et al., <i>Biochem. Biophys. Res. Commun.</i> , 282:356-360 (2001)
105	Bar-Or et al., <i>Free Rad. Biol. Med.</i> , 32(2):197-199 (2002)
106	Bar-Or et al., abstr. P416 In American Peptide Society "Abstract Book" from 17th American Peptide Symposium, San Diego, California, June 2001
107	Bar-Or et al., <i>Biochem. Biophys. Res. Commun.</i> , 290:1388-1392 (2002)
108	Bar-Or et al., text of poster presented at 17th American Peptide Symposium, San Diego, California, June 2001, found at http://www.5z.com/aps/7/2/19/02
109	Beaulieu et al., <i>J. Cerebral Blood Flow and Metabolism</i> , 18:1022-1031 (1998)
110	Belayev et al., <i>J. Neurotrauma</i> , 16(6):445-453 (1999)
111	Boggs, "Copper chelation suppresses experimental liver tumor growth," found at http://www.buntsmancancer.org/content/reuters/2001/12/21/200112221scle001.html, January 28, 2002
112	Bossu et al., <i>Inorganic Chemistry</i> , 17(4):1034-1042 (1978)
113	Bourdon et al., <i>FASEB J.</i> , 13:233-244 (1999)
114	Buranaprapuk et al., <i>Biochim Biophys Acta</i> , 1387:309-316 (1998)
115	Calabrese et al., <i>Biochem. J.</i> , 238:291-295 (1986)
116	Canters et al., <i>FEBS</i> , 325(1,2):39-48 (1993)
117	Chakrabarti, <i>Protein Engineering</i> , 4(1):57-63 (1990)
118	Chan et al., <i>Eur. J. Biochem.</i> , 227:524-528 (1995)
119	Cotelle et al., <i>J. Inorganic Biochemistry</i> , 46:7-15 (1992)
120	Das et al., <i>Methods in Enzymology</i> , 233:601-611 (1994)
121	Davies, <i>J. Biol. Chem.</i> , 262(20):9902-9907 (1987)
122	Davies, <i>J. Biol. Chem.</i> , 262(20):9895-9901 (1987)
123	Davies, <i>J. Biol. Chem.</i> , 262(20):9914-9920 (1987)
124	Davies, <i>J. Biol. Chem.</i> , 262(20):9908-9913 (1987)
125	Duchette et al., "Copper Reduction Therapy as an Antiangiogenic Treatment for Lymphoma and other Cancers," found at http://www.coldcure.com/html/anti-ang.htm, 3/5/01, 23 pages

EXAMINER 	DATE CONSIDERED 9/14/04
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT BAR-OR et al.	
		FILING DATE February 13, 2002	GROUP ART 1614

AD	126	Dunphy et al., <i>Am. J. Physiol.</i> , 276:H1591-H1598 (1999)
AD	127	Farkas et al., <i>J. Chem. Soc. Dalton Trans.</i> , pp. 611-614 (1984)
AD	128	Florence, <i>Australian and New Zealand J. Ophthalmol.</i> , 23(1):3-7 (1995)
AD	129	Fu et al., <i>Biochem. J.</i> , 333:519-525 (1998)
AD	130	Gutteridge et al., <i>Biochim. Biophys. Acta</i> , 759:38-41 (1983)
AD	131	Halliwell et al., <i>Arch. Biochem. Biophys.</i> , 246(2):501-514 (1986)
AD	132	Halliwell et al., "Free Radicals in Biology and Medicine" pp. 1-21 (2nd ed. Clarendon Press - Oxford 1989)
AD	133	Halliwell et al., <i>Arch. Biochem. Biophys.</i> , 280(1):1-8 (1990)
AD	134	Harford et al., <i>Acc. Chem. Res.</i> , 30:123-130 (1997)
AD	135	He et al., <i>Biochemistry</i> , 38:9704-9711 (1999)
AD	136	Hirose et al., <i>Biochim. Biophys. Acta</i> , 1296:103-111 (1996)
AD	137	Hisatomi et al., <i>Transplantation</i> , 52(4):754-755 (1991)
AD	138	Huh et al., <i>Brain Res.</i> , 804:105-113 (1998)
AD	139	Karck et al., <i>J. Heart Lung Transplant</i> , 11:979-85 (1992)
AD	140	Keller et al., <i>Chem. Res. Toxicol.</i> , 6:430-433 (1993)
AD	141	Kerr et al., <i>Heart Lung</i> , 25:200-9 (1996)
AD	142	Khan et al., <i>Biochem. Pharmacol.</i> , 43(9):1963-1967 (1992)
AD	143	Kimoto et al., <i>Cancer Res.</i> , 43(2):824-828 (1983) Abstr. in PubMed- PMID: 6293704
AD	144	Knight, <i>Ann. Clin. Lab. Sci.</i> , 25(2):111-121 (1995)
AD	145	Koch et al., <i>Chemistry & Biology</i> , 4:549-560 (1997)
AD	146	Kowalik-Jankowska et al., "Copper(II) Complexes with Oligopeptides Containing Serine, Methionine or Phenylalanine Residues" pp. 1184-1197 (9/24/1992)
AD	147	Kowalik-Jankowska et al., <i>J. Inorg. Biochem.</i> , 66:193-196 (1997)
AD	148	Kruck et al., <i>Can. J. Chem.</i> , 54:1300-1308 (1976)
AD	149	Lappin et al., <i>Inorganic Chemistry</i> , 17(6):1630-1634 (1978)
AD	150	Lau et al., <i>Biochem J.</i> , 257(3) 745-750 (1989) Abstr. in PubMed- PMID: 2467660
AD	151	Laussac et al., <i>Biochemistry</i> , 23:2832-2838 (1984)
AD	152	Leeuwenburgh et al., <i>Am J. Physiol.</i> , 274:R453-R461 (1998)
AD	153	Legrand et al., <i>Biochimie</i> , 70:1185-1195 (1988)
AD	154	Little et al., <i>Neurosurgery</i> , 9(5):552-558 (1981)
AD	155	Loban et al., <i>Clinical Science</i> , 93:445-451 (1997)












EXAMINER	DATE CONSIDERED 9/18/04
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	


FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
	APPLICANT BAR-OR et al.	
	FILING DATE February 13, 2002	GROUP ART 1614


156	Machonkin et al., <i>Biochemistry</i> , 37:9570-9578 (1998)
157	Malins et al., <i>Proc. Natl. Acad. Sci USA</i> , 93:2557-2565 (1996)
158	Malmström et al., <i>Curr Op. Chem. Biol.</i> , 2:286-292 (1998)
159	Manso, <i>Rev. Port. Cardiol.</i> , 11(11):997-999 (1992)
160	Maret et al., <i>Methods in Enzymology</i> , 226:52-71 (1993)
161	Marx et al., <i>Biochem. J.</i> , 236:397-400 (1985)
162	Masuoka et al., <i>J. Biol. Chem.</i> , 268(29):21533-21537 (1993)
163	McGuire et al., <i>Curr. Op. Chem. Biol.</i> , 3:138-144 (1999)
164	Miller et al., <i>Arch. Biochem. Biophys.</i> , 295(2):240-246 (1992)
165	Mlynarz et al., "α-Hydroxymethylserine (HMS) Makes HMS-HMS-His the Most Efficient Tripeptide Ligand for Cu ²⁺ Ions" (1998) Speciation 98:Abstract
166	Musci et al., <i>Arch. Biochem. Biophys.</i> , 306(1):111-118 (1993)
167	Odeh, <i>N Eng. J. Med.</i> , 324(20):1417-1422 (1991)
168	Praticò et al., <i>J. Clin. Invest.</i> , 100(8):2028-2034 (1997)
169	Predki et al., <i>Biochem. J.</i> , 287:211-215 (1992)
170	Quinlan et al., <i>J. Pharm. Sci.</i> , 81(7):611-614 (1992)
171	Rao et al., <i>Ann. Thorac. Surg.</i> , 52:908-12 (1991)
172	Regan, <i>Annu. Rev. Biophys. Biomol. Struct.</i> , 22:257-81 (1993)
173	Regan, <i>TIBS</i> 20, pp. 280-285 (1995)
174	Remmers et al., <i>Brain Research</i> , 827:237-242 (1999)
175	Rosenthal et al., <i>Free Radical Biology & Medicine</i> , 12:29-33 (1992)
176	Röth, <i>Acta Chirurgica Hungarica</i> , 36(1-4):302-305 (1997)
177	Rupp et al., <i>Biochim. Biophys. Acta.</i> , 446:151-165 (1976)
178	Russell et al., <i>Free Radical Biology & Medicine</i> , 25(2):153-159 (1998)
179	Rylkov et al., <i>Eur. J. Biochem.</i> , 197:185-189 (1991)
180	Sadler et al., <i>Eur. J. Biochem.</i> , 220:193-200 (1994)
181	Salvemini et al., <i>Science</i> , 286:304-306 (1999)
182	Si et al., <i>GLIA</i> , 21:413-418 (1997)
183	Smith et al., <i>J. Histochem. Cytochem.</i> , 46:731-735 (1998)
184	Spencer et al., <i>J. Cardiovasc. Pharmacol.</i> , 32(3):343-348 (1998)
185	Stohs, <i>J. Basic & Clin. Physiol. Pharmacol.</i> , 6(3-4):205-229 (1995)

EXAMINER	DATE CONSIDERED 9/14/04
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076.071
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT BAR-OR et al.	
FILING DATE February 13, 2002		GROUP ART 1614	

	186	Sutherland et al., abstr. P078 in Abstracts of Communications to be presented at the 10th International Congress on Cardiovascular Pharmacotherapy, Kyoto Japan, March 2001
	187	Sutherland et al., <i>J. Cardio. Pharmacol.</i> , 39:722-728 (200-2)
	188	Süzer et al., <i>Pharmacol. Res.</i> , 37(2):97-101 (1998)
	189	Ueda et al., <i>Chem. Pharm. Bull.</i> , 43(2):359-361 (1995)
	190	Ueda et al., <i>Free Radical Biology & Medicine</i> , 18(5):929-933 (1995)
	191	Ueda et al., <i>J. Inorgan. Biochem.</i> , 55:123-130 (1994)
	192	Whittall et al., <i>Protein Science</i> , 9:332-343 (2000)
	193	Wolff et al., <i>TIBS</i> 11, pp. 27-31 (1986)
	194	Wysocki et al., <i>Coronary Artery Disease</i> , 4:645-647 (1993)
	195	Yamada et al., <i>Biochem. Mol. Biol. Intl</i> , 46(4):733-738 (1998)
	V	Yoon et al., <i>J. Surg Res</i> , 46:163-165 (1989)

EXAMINER 	DATE CONSIDERED 9/14/04
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

SHEET 1 OF 1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
	APPLICANT BAR-OR et al.	
	FILING DATE February 13, 2002	GROUP ART 1653

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
<i>AB</i>	AA	6,001,965	12/14/1999	Livant	530	330	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
<i>AB</i>	AB	WO 02/064621	8/22/2002	PCT	530	330		
<i>AB</i>	AC	WO 00/13712	3/16/2000	PCT	530	330		

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

EXAMINER <i>AB</i>	DATE CONSIDERED <i>9/14/04</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



SHEET 1 OF 2

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
	APPLICANT BAR-OR et al.	
	FILING DATE February 13, 2002	GROUP ART 1653

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
<i>AD</i>	1	6,610,821	8/26/2003	Blaschuk et al.	530	317	
<i>AD</i>	2	2003/0130185	7/10/2003	Bar-Or et al.	514	12	6/27/2002
<i>AD</i>	3	6,583,182	6/24/2003	Winchell et al.	514	648	
<i>AD</i>	4	6,264,966	7/24/2001	Winchell et al.	424	401	
<i>AD</i>	5	09/678,202		Bar-Or et al.			9/29/2000
<i>AD</i>	6	6,008,205	12/28/1999	Serhan et al.	514	102	
<i>AD</i>	7	5,932,548	8/3/1999	Deghenghi	514	15	
<i>AD</i>	8	5,919,900	7/6/1999	Moyle et al.	530	350	
<i>AD</i>	9	5,529,907	6/25/1996	Nierman et al.	435	29	
<i>AD</i>	10	5,270,447	12/14/1993	Liotta et al.	530	326	
<i>AD</i>	11	4,975,423	12/4/1990	Gaffar	514	108	
<i>AD</i>	12	4,816,449	3/28/1989	Hahn	514	17	
<i>AD</i>	13	4,628,045	12/9/1986	Hahn	514	17	
<i>AD</i>	14	4,323,558	4/6/1982	Nelson	424	164	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
<i>AD</i>	15	WO 02/43722	6/6/2002	PCT	A61K	31/132		
<i>AD</i>	16	WO 00/23469	4/27/2000	PCT	C07K	14/47		
<i>AD</i>	17	WO 94/14836	7/7/1994	PCT	C07K	1/02		
<i>AD</i>	18	WO 94/09808	5/11/1994	PCT	A61K	37/02		

EXAMINER <i>AD</i>	DATE CONSIDERED <i>9/18/04</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

SHEET 2 OF 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
	APPLICANT BAR-OR et al.	
	FILING DATE February 13, 2002	GROUP ART 1653

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

	19	Ben-Hamida et al.; "Histamine, Xanthine Oxidase Generated Oxygen-Derived Free Radicals and Helicobacter Pylori in Gastroduodenal Inflammation and Ulceration"; <i>Inflammation Research</i> ; 1998; 47:193-199
	20	Cameron et al.; "Neurovascular Dysfunction in Diabetic Rats. Potential Contribution of Autoxidation and Free Radicals Examined Using Transition Metal Chelating Agents"; <i>J Clin Invest</i> ; August 1995; 96(2):1159-63; 1 p. Abstract from NCBI PubMed; PMID: 7635953
	21	Danielsson et al.; "Nonopsonic Activation of Neutrophils by Helicobacter Pylori is Inhibited by Rebamipide"; <i>Digestive Diseases and Sciences</i> ; September 1998 Supplement; 43(9):167S-173S
	22	Iinuma et al.; "Role of Active Oxygen Species and Lipid Peroxidation in Mepirizole-Induced Duodenal Ulcers in Rats"; <i>Digestive Diseases and Sciences</i> ; August 1998; 43(8):1657-1664
	23	Love et al.; "Nerve Function and Regeneration in Diabetic and Galactosaemic Rats: Antioxidant and Metal Chelator Effects"; <i>Eur J Pharmacol</i> ; October 24, 1996; 314(1-2):33-9; 1 p. Abstract from NCBI PubMed; PMID: 8957216
	24	Yoshii et al.; "The Copper-Chelating Agent, Trientine, Suppresses Tumor Development and Angiogenesis in the Murine Hepatocellular Carcinoma Cells"; <i>Int J Cancer</i> ; December 15, 2001; 94(6):768-73; 1 p. Abstract from NCBI PubMed; PMID: 11745476

EXAMINER	DATE CONSIDERED 9/14/04
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and * not considered. Include copy of this form with next communication to applicant.	